Company news
Entrada Therapeutics, Inc. news in 2022
Entrada Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.
Entrada Therapeutics Announces Clinical Hold on IND Application for ENTR-601-44 in Duchenne Muscular Dystrophy
December 18, 2022
Vertex and Entrada Therapeutics Establish Collaboration to Discover and Develop Endosomal Escape Vehicle (EEV) Therapeutics for Myotonic Dystrophy Type 1 (DM1)
December 7, 2022
Entrada Therapeutics to Present at Evercore ISI 5th Annual HealthCONx Virtual Conference
November 21, 2022
Entrada Therapeutics Reports Third Quarter 2022 Financial Results
November 6, 2022
Entrada Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference
August 29, 2022
Entrada Therapeutics Reports Second Quarter 2022 Financial Results
August 10, 2022
Entrada Therapeutics Announces Collaboration with the Myotonic Dystrophy Clinical Research Network to Study the Natural History of Myotonic Dystrophy Type 1
August 3, 2022
Entrada Therapeutics Appoints Karla MacDonald as Chief Corporate Affairs Officer
July 18, 2022
Entrada Therapeutics to Present at William Blair Biotech Focus Conference
July 5, 2022
Entrada Therapeutics to Present at Goldman Sachs Global Healthcare Conference
May 31, 2022
Entrada Therapeutics Reports First Quarter 2022 Financial Results
May 11, 2022
Entrada Therapeutics Presents New Data Supporting its Growing Pipeline of Endosomal Escape Vehicle (EEV™) Therapeutics at TIDES USA 2022
May 10, 2022
Entrada Therapeutics to Present at H.C. Wainwright Global Investment Conference
May 9, 2022
Entrada Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
March 14, 2022
Entrada Therapeutics to Participate in Cowen 42nd Annual Health Care Conference
February 22, 2022
Entrada Therapeutics Announces the Appointment of Jared Cohen, PhD, JD to General Counsel
January 4, 2022
Decks in 2022
- MDF 2022
Conference · 12 slides · 2022